Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
74 hedge funds and large institutions have $319M invested in Aimmune Therapeutics in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 13 reducing their positions, and 8 closing their positions.
208% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 13
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
7% more funds holding
Funds holding: 69 → 74 (+5)
14% less capital invested
Capital invested by funds: $372M → $319M (-$53.8M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$10.4M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$10M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$5.76M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.84M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$13.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.07M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$3.99M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.81M |
| 5 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.63M |
AIMT Hedge Fund Activity: Q2 2016 in Review
74 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2016, worth a combined $319M — down 14% from $372M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AIMT positions and 8 closed out — a net gain of 5 holders — while 40 added to existing stakes and 13 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $10.4M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $13.3M sold.
- 74 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2016, up from 69 in Q1 2016.
- Funds reported $319M of Aimmune Therapeutics stock for Q2 2016, down 14% quarter-over-quarter.
- 13 funds opened new Aimmune Therapeutics positions in Q2 2016 and 8 closed out, a net change of +5 holders.
- The largest Aimmune Therapeutics buyer in Q2 2016 was Vivo Capital, an estimated $10.4M added.
- The largest Aimmune Therapeutics seller in Q2 2016 was Sectoral Asset Management, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2016.